CADD: predicting the deleteriousness of variants throughout the human genome
The GSTM1 null genotype has been associated in various populations with increased risk of several cancers, including gastric and prostate cancer, particularly in the context of additional risk factors such as Helicobacter pylori infection or smoking
This topic is complex and controversial, but Im excited for you to listen (and feedback or questions are always welcome)
It can be used as both injection-type or oral-type drug.[9] The marketing authorization in EU was granted on 8 February 2018.[10] It is still under review by regulatory authorities in Japan, pending approval.[11] ------------------------------------- Reported by Jules Levin AASLD 2018 Nov 9-13 SF Philip N Newsome1 ,2, Stephen A Harrison3, Sren Rasmussen4, Tea Monk Fries4, Luc Van Gaal5 1National Institute for Health Research Birmingham Biomedical Research Centre and Liver Unit at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
You get medical supervision